ElevateBio adds another $525M to its war chest as it looks to build on next-gen manufacturing 'basecamp'

Kyle Blankenship

Despite immense clinical promise, small cell and gene therapy players have faced a chronic manufacturing bottleneck tied to limited cash and specialized expertise. Born from …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

ElevateBio adds another $525M to its war chest as it looks to build on next-gen manufacturing 'basecamp'

Kyle Blankenship

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Versant unveils Light Horse with $62M and a partnership with Novartis

After lackluster 2024, biopharma industry prays stalled M&A will finally move into gear

IGM Biosciences’ autoimmune pivot lasts three months after interim data disappoint

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Shoreline cuts staff as its partnership with Gilead's Kite is now in flux

El­e­vate­Bio adds an­oth­er $525M to its war chest as it looks to build on next-gen man­u­fac­tur­ing 'base­cam­p'

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

ElevateBio adds another $525M to its war chest as it looks to build on next-gen manufacturing 'basecamp'